Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218199 · ClinicalTrials.gov registry record · Phase 4
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
A Phase 4 study of Heart Failure, Congestive, sponsored by Heart Center Research.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06218199: Recruiting Phase 4 study of Heart Failure, Congestive, sponsored by Heart Center Research.
NCT06218199 is a Phase 4 study of Heart Failure, Congestive that is actively recruiting participants, run by Heart Center Research. The registered enrollment target is 80 participants, below the 673-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06218199, a Phase 4 study of Heart Failure, Congestive, is actively recruiting participants, sponsored by Heart Center Research.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.
Primary Outcome
change in HeartLogic score to ≤ 6
Conditions Studied
Interventions
- DRUG Furosemide
- DRUG Bumetanide
- DRUG Torsemide
- DRUG sacubitril/valsartan
- DRUG Hydralazine
Study Locations (1)
Alabama
- Heart Center Research, LLC - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT06218199 shows while recruiting
NCT06218199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 673-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 5 interventions - of which Furosemide is the first listed.
NCT06218199 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06218199 about?
NCT06218199 is a clinical study titled "Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts". The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic hea...
What is the current status of trial NCT06218199?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2021-07-08. Estimated completion is 2026-12-31.
What conditions does trial NCT06218199 study?
This clinical trial studies the following conditions: Heart Failure, Congestive.
What interventions are being tested in trial NCT06218199?
The interventions under investigation include: Furosemide (DRUG), Bumetanide (DRUG), Torsemide (DRUG), sacubitril/valsartan (DRUG), Hydralazine (DRUG).
Who is sponsoring clinical trial NCT06218199?
This trial is sponsored by Heart Center Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218199 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06218199's enrollment target sits among peer trials
80 27th of 39 higher than 12 of 39 other Heart Failure, Congestive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure, Congestive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise Effect on Aerobic Capacity and QOL in Heart Failure
COMPLETED · Phase 4
-
Effects of Carvedilol on Health Outcomes in Heart Failure
COMPLETED · Phase 4
-
Statin Therapy in Heart Failure: Potential Mechanisms of Benefit
COMPLETED · Phase 4
-
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
COMPLETED · Phase 4
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI